LLY Jan 2025 290.000 call
| Previous close | 472.68 |
| Open | 472.68 |
| Bid | 457.25 |
| Ask | 464.90 |
| Strike | 290.00 |
| Expiry date | 2025-01-17 |
| Day's range | 472.68 - 472.68 |
| Contract range | N/A |
| Volume | |
| Open interest | 18 |
Insider MonkeyEli Lilly and Company (LLY) Rose due to Robust Q4 Sales
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
ZacksEli Lilly (LLY) Advances But Underperforms Market: Key Facts
Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.
- Reuters
Eli Lilly to acquire manufacturing facility from Nexus Pharma
Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines. Lilly expects production at the facility based in Pleasant Prairie, Wisconsin, to begin at the end of 2025. Soaring demand for GLP-1 agonists, a class of highly effective diabetes and obesity drugs which suppress appetite and promote a feeling of fullness, has led to constrained supply for drugmakers such as Lilly and Danish drugmaker Novo Nordisk .
